

**DOTT. NICOLA STEFANO FRACCHIOLLA**

**CURRICULUM FORMATIVO E PROFESSIONALE**

Data e luogo di nascita: 24/3/1967 a Milano

Residenza: Via Primo Maggio 39D1  
20090 Buccinasco  
Tel/Fax: 02-45700390  
Tel cell: 348-2252946

e-mail: n.fracchiolla@policlinico.mi.it

**Curriculum Studiorum**

Laureato in Medicina e Chirurgia presso l'Università degli Studi di Milano il 21/10/1992 con voto 110/110 e Lode con tesi sperimentale dal titolo: "Linfomi Splenomidollari a cellule B: caratterizzazione immunocitomorfológica, citogenetica e genotipica di 15 casi"

Consegue il Diploma di Specialità in Ematologia presso la Scuola di Ematologia I (Dir. Prof. AT Maiolo) dell'Università degli Studi di Milano il 14/11/1996 con voto 70/70 e Lode con tesi sperimentale dal titolo: "Caratterizzazione biologico molecolare di 90 casi di linfoma cutaneo a B e T cellule".

Nell'anno 2008 ha conseguito la Specialità in Oncologia presso l'Università degli Studi di Milano con 70/70 e lode.

Nell'anno 2009 ha conseguito il Master in Economia Sanitaria applicato all'ematologia presso il Centro Studi ISTUD con una tesi dal titolo "Benchmark sui principali cost drivers in differenti realtà regionali: il caso del trattamento di induzione della leucemia mieloide acuta: implicazioni per la valutazione della congruità della tariffa", con citazione sul Sole24Ore Sanità del novembre 2009.

Nell'anno 2009/2010 ha conseguito il Master Universitario di II livello in Gestione ed Organizzazione delle Strutture Ospedaliere, presso l'università Carlo Cattaneo LIUC di Castellanza, Facoltà di Economia Aziendale con una tesi dal titolo "posizionamento dell'unità operativa complessa di ematologia della Fondazione IRCCS Ca' Granda – Ospedale maggiore Policlinico nell'ambito di aziende ospedaliere con unità operative omogenee della Lombardia".

**Lingue**

Inglese: scritto e parlato: ottimo (Cambridge Proficiency in English)

**Ha acquisito l'abilitazione scientifica nazionale a Professore di seconda Fascia**

**Lista delle Pubblicazioni in extenso su riviste censite (124, H index 30, si riportano solo quelle dal 2019)**

**Bibliografia 2020-2022**

- 1: Candoni A, Lazzarotto D, Papayannidis C, Piccini M, Nadali G, Dargenio M, Riva M, Fracchiolla N, et al. prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with venetoclax. *Am J Hematol.* 2023 Jan 18. doi: 10.1002/ajh.26846. Epub ahead of print. PMID: 36651870.
- 2: Cattaneo C, Salmanton-García J, Marchesi F, El-Ashwah S, Itri F, Weinbergerová B, Gomes Da Silva M, Dargenio M, Dávila-Valls J, Martín-Pérez S, Farina F, Van Doesum J, Valković T, Besson C, Poulsen CB, López-García A, Žák P, Schönlein M, Piukovics K, Jaksic O, Cabirta A, Ali N, Sili U, Fracchiolla N, et al. Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey. *Cancers (Basel).* 2022 Nov 10;14(22):5530. doi: 10.3390/cancers14225530. PMID: 36428621; PMCID: PMC9688278.
- 3: Dargenio M, Bonifacio M, Chiaretti S, Vitale A, Fracchiolla NS, et al. Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric- inspired regimens: A retrospective multicentre Campus ALL study. *Br J Haematol.* 2022 Nov 6. doi: 10.1111/bjh.18537. Epub ahead of print. PMID: 36335916.
- 4: Merli M, Ferrarini I, Merli F, Busca A, Mina R, Falini B, Bruna R, Cairoli R, Marchetti M, Romano A, Cavo M, Arcaini L, Trentin L, Cattaneo C, Derenzini E, Fracchiolla NS, et al. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. *Hematol Oncol.* 2022 Oct 20. doi: 10.1002/hon.3092. Epub ahead of print. PMID: 36265128.
- 5: Defina M, Lazzarotto D, Guolo F, Minetto P, Fracchiolla NS, et al. Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group. *Leuk Res.* 2022 Nov;122:106963. doi: 10.1016/j.leukres.2022.106963. Epub 2022 Sep 21. PMID: 36155352.
- 6: Pagano L, Salmanton-García J, Marchesi F, Blennow O, Gomes da Silva M, Glenthøj A, van Doesum J, Bilgin YM, López-García A, Itri F, Nunes Rodrigues R, Weinbergerová B, Farina F, Dragonetti G, Berg Venemyr C, van Praet J, Jaksic O, Valković T, Falces-Romero I, Martín-Pérez S, Jiménez M, Dávila-Valls J, Schönlein M, Ammatuna E, Meers S, Delia M, Stojanoski Z, Nordlander A, Lahmer T, Imre Pinczés L, Buquicchio C, Piukovics K, Ormazabal-Vélez I, Fracchiolla N, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. *Blood.* 2022 Dec 29;140(26):2773-2787. doi: 10.1182/blood.2022017257. PMID: 36126318; PMCID: PMC9492383.
- 7: Del Principe MI, Seidel D, Criscuolo M, Dargenio M, Ráčil Z, Piedimonte M, Marchesi F, Nadali G, Koehler P, Fracchiolla N, et al. FUNGISCOPE (Global Emerging Fungal Infection Registry) and the SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie). Clinical features and prognostic factors of *Magnusiomyces (Saprochaete)* infections in haematology. A multicentre study of SEIFEM/Fungiscope. *Mycoses.* 2023 Jan;66(1):35-46. doi: 10.1111/myc.13524. Epub 2022 Sep 19. PMID: 36064299.
- 8: Jonas BA, DiNardo C, Fracchiolla N, Pristupa A, Ishizawa K, Jin J, Konopleva M, Ofran Y, Montesinos P, Kovacsovics T, Jang JH, Kantarjian H, Duan Y, Potluri J, Werner M, Pratz KW. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. *Am J Hematol.* 2022 Nov;97(11):E422-E425. doi: 10.1002/ajh.26707. Epub 2022 Sep 16. PMID: 36053878.
- 9: Arniani S, Pierini V, Pellanera F, Matteucci C, Di Giacomo D, Bardelli V, Quintini M, Mavridou E, Lema Fernandez AG, Nardelli C, Moretti M, Gorello P, Crescenzi B, Romoli S, Beacci D, Cerrano M, Fracchiolla N, Sica S, Forghieri F, Giglio F, Dargenio M, Elia L, La Starza R, Mecucci C. Chromothripsis is a frequent event and underlies typical genetic changes in early T-cell precursor lymphoblastic leukemia in adults. *Leukemia.* 2022 Nov;36(11):2577-2585. doi: 10.1038/s41375-022-01671-5. Epub 2022 Aug 16. PMID: 35974102; PMCID: PMC9613476.
- 10: Manzoni M, Bosi A, Fabris S, Lionetti M, Salerio S, Migliorini AC, Cavallaro F, Barbullushi K, Rampi N, Montefusco V, Alessio MG, Neri A, Baldini L, Sciumè M, Tagliaferri E, Fracchiolla N, Bolli N. Clinical,

Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine. *Clin Hematol Int.* 2022 May 12;4(1-2):52-55. doi: 10.1007/s44228-022-00002-w. PMID: 35950209; PMCID: PMC9358783.

11: Steffanoni S, Calimeri T, Laurence A, Fox CP, Soussain C, Grommes C, Tisi MC, Boot J, Crosbie N, Visco C, Arcaini L, Chaganti S, Sassone MC, Alencar A, Armiento D, Romano I, Dietrich J, Itchaki G, Bruna R, Fracchiolla NS, et al. Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group. *Br J Haematol.* 2022 Nov;199(4):507-519. doi: 10.1111/bjh.18396. Epub 2022 Aug 9. PMID: 35945164; PMCID: PMC9538907.

12: Criscuolo M, Salmanton-García J, Fracchiolla N, et al. SARS-CoV-2 Infection among Patients with Mastocytosis: An EPICOVIDEHA Report. *J Investig Allergol Clin Immunol.* 2022 Jul 26:0. doi: 10.18176/jiaci.0845. Epub ahead of print. PMID: 35894666.

13: Barbullushi K, Rampi N, Serpenti F, Sciumè M, Fabris S, De Roberto P, Fracchiolla NS. Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand? *Cancers (Basel).* 2022 Jun 17;14(12):2994. doi: 10.3390/cancers14122994. PMID: 35740657; PMCID: PMC9221207.

14: Cattaneo C, Marchesi F, Terrenato I, Bonuomo V, Fracchiolla NS, Delia M, Criscuolo M, Candoni A, Prezioso L, Facchinelli D, Pasciolla C, Del Principe MI, Dargenio M, Buquicchio C, Mitra ME, Farina F, Borlenghi E, Nadali G, Gagliardi VP, Fianchi L, Sciumè M, Menna P, Busca A, Rossi G, Pagano L. High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study. *J Fungi (Basel).* 2022 May 29;8(6):583. doi: 10.3390/jof8060583. PMID: 35736066; PMCID: PMC9224885.

15: Serpenti F, Sciumè M, Galassi G, Saporiti G, Grifoni F, Rampi N, Cavallaro F, Barbullushi K, Tagliaferri E, Goldaniga M, Baldini L, Fracchiolla NS, Onida F. Off-label venetoclax in combination with hypomethylating agents for post- allogeneic stem cell transplant acute myeloid leukemia relapse. *Leuk Lymphoma.* 2022 Nov;63(11):2743-2746. doi: 10.1080/10428194.2022.2090553. Epub 2022 Jun 22. PMID: 35730459.

16: Blennow O, Salmanton-García J, Nowak P, Itri F, Van Doesum J, López-García A, Farina F, Jaksic O, Pinczés LI, Bilgin YM, Falces-Romero I, Jiménez M, Ormazabal-Vélez I, Weinbergerová B, Duléry R, Stojanoski Z, Lahmer T, Fernández N, Hernández-Rivas JÁ, Petzer V, De Jonge N, Glenthøj A, De Ramón C, Biernat MM, Fracchiolla N, et al. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report. *Am J Hematol.* 2022 Aug;97(8):E312-E317. doi: 10.1002/ajh.26626. Epub 2022 Jun 28. PMID: 35702878; PMCID: PMC9349555.

17: Marchesi F, Salmanton-García J, Emarah Z, Piukovics K, Nucci M, López-García A, Ráčil Z, Farina F, Popova M, Zompi S, Audisio E, Ledoux MP, Verga L, Weinbergerová B, Sztokovski T, Da Silva MG, Fracchiolla N, et al EPICOVIDEHA working group. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). *Haematologica.* 2023 Jan 1;108(1):22-33. doi: 10.3324/haematol.2022.280847. PMID: 35545919; PMCID: PMC9827164.

18: Pratz KW, Panayiotidis P, Recher C, Wei X, Jonas BA, Montesinos P, Ivanov V, Schuh AC, DiNardo CD, Novak J, Pejsa V, Stevens D, Yeh SP, Kim I, Turgut M, Fracchiolla N, Yamamoto K, Ofran Y, Wei AH, Bui CN, Benjamin K, Kamalakar R, Potluri J, Mendes W, Devine J, Fiedler W. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. *Blood Cancer J.* 2022 Apr 20;12(4):71. doi: 10.1038/s41408-022-00668-8. PMID: 35443742; PMCID: PMC9021259.

19: Buzzatti E, Forghieri F, Paterno G, Marchesi F, Sarlo C, Giglio F, Fracchiolla N, Sciumè M, Palmieri R, Esposito F, Guarnera L, Mercante L, Pascale MR, Mallegni F, Savi A, Forte V, Maurillo L, Buccisano F, Venditti A, Del Principe MI. In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia. *J Clin Med.* 2022 Mar 23;11(7):1776. doi: 10.3390/jcm11071776. PMID: 35407383; PMCID: PMC8999266.

20: Bonifacio M, Papayannidis C, Lussana F, Fracchiolla N, Annunziata M, Sica S, Delia M, Foà R, Pizzolo G, Chiaretti S. Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.

Front Oncol. 2022 Jan 6;11:804714. doi: 10.3389/fonc.2021.804714. PMID: 35071008; PMCID: PMC8770323.

21: Cerrano M, Bonifacio M, Olivi M, Curti A, Malagola M, Dargenio M, Scattolin AM, Papayannidis C, Forghieri F, Gurrieri C, Tanasi I, Zappasodi P, La Starza R, Fracchiolla NS, et al. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study. *Haematologica*. 2022 Apr 1;107(4):996-999. doi: 10.3324/haematol.2021.279851. PMID: 35021604; PMCID: PMC8968887.

22: Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, Döhner H. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. *J Clin Oncol*. 2022 Mar 10;40(8):855-865. doi: 10.1200/JCO.21.01546. Epub 2021 Dec 15. PMID: 34910556; PMCID: PMC8906463.

23: Del Principe MI, Dragonetti G, Conti A, Verga L, Ballanti S, Fanci R, Candoni A, Marchesi F, Cattaneo C, Lessi F, Fracchiolla N, Spolzino A, Prezioso L, Delia M, Potenza L, Decembrino N, Castagnola C, Nadali G, Picardi M, Zama D, Orciulo E, Veggia B, Garzia M, Dargenio M, Melillo L, Manetta S, Russo D, Mancini V, Piedimonte M, Tisi MC, Toschi N, Busca A, Pagano L; behalf of the SEIFEM group; Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) group. Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey. *Mycoses*. 2022 Feb;65(2):171-177. doi: 10.1111/myc.13384. Epub 2021 Dec 3. PMID: 34695256.

24: Visco C, Marcheselli L, Mina R, Sassone M, Guidetti A, Penna D, Cattaneo C, Bonuomo V, Busca A, Ferreri AJM, Bruna R, Petrucci L, Cairoli R, Salvini M, Bertù L, Ladetto M, Pileri S, Pinto A, Ramadan S, Marchesi F, Cavo M, Arcaini L, Coviello E, Romano A, Musto P, Massaia M, Fracchiolla N, et al; ITA-HEMA-COV investigators. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. *Blood Adv*. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691. PMID: 34644385; PMCID: PMC8516438.

25: Del Principe MI, Dragonetti G, Conti A, Verga L, Ballanti S, Fanci R, Candoni A, Marchesi F, Cattaneo C, Lessi F, Fracchiolla N, et al; behalf of the SEIFEM group; Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) group. Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey. *Mycoses*. 2022 Feb;65(2):171-177. doi:10.1111/myc.13384. Epub 2021 Dec 3. PMID: 34695256.

26: Pagano L, Salmanton-García J, Marchesi F, et al; EPICOVIDEHA working group. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). *J Hematol Oncol*. 2021 Oct 14;14(1):168. doi: 10.1186/s13045-021-01177-0. PMID: 34649563; PMCID: PMC8515781.

27: Visco C, Marcheselli L, Mina R, et al.; ITA-HEMA-COV investigators. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. *Blood Adv*. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691. PMID: 34644385; PMCID: PMC8516438.

28: Efficace F, Platzbecker U, Breccia M, Cottone F, Carluccio P, Salutari P, DiBona E, Borlenghi E, Autore F, Levato L, Finizio O, Mancini V, D'Ardia S, Schlenk RF, Melillo L, Fumagalli M, Fiedler W, Beltrami G, Fracchiolla NS, Bernardi M, Fazi P, Annibaldi O, Mayer K, Voso MT, Vignetti M. Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. *Blood Adv*. 2021 Nov 9;5(21):4370-4379. doi:10.1182/bloodadvances.2021004649. PMID: 34529768; PMCID: PMC8579253.

29: Saccon E, Bandera A, Sciumè M, Mikaeloff F, Lashari AA, Aliberti S, Sachs MC, Billi F, Blasi F, Gabriel EE, Costantino G, De Roberto P, Krishnan S, Gori A, Peyvandi F, Scudeller L, Canetta C, Lorson CL, Valenti L, Singh K, Baldini L, Fracchiolla NS; COVID-19 Network Working Group, Neogi U. Distinct Metabolic Profile Associated with a Fatal Outcome in COVID-19 Patients during the Early Epidemic in Italy. *Microbiol Spectr*. 2021 Oct 31;9(2):e0054921. doi:10.1128/Spectrum.00549-21. Epub 2021 Sep 1. PMID: 34468185; PMCID: PMC8565516.

30: Passamonti F, Romano A, Salvini M, Merli F, Porta MGD, Bruna R, Coviello E, Romano I, Cairoli R, Lemoli R, Farina F, Venditti A, Busca A, Ladetto M, Massaia M, Pinto A, Arcaini L, Tafuri A, Marchesi F, Fracchiolla N, et al; ITA-HEMA-COV Investigators\*. COVID-19 elicits an impaired antibody response against

SARS-CoV-2 in patients with haematological malignancies. *Br J Haematol.* 2021 Nov;195(3):371-377. doi: 10.1111/bjh.17704. Epub 2021 Jul 16. PMID: 34272724; PMCID: PMC8444788.

31: Busca A, Cattaneo C, De Carolis E, Nadali G, Offidani M, Picardi M, Candoni A, Ceresoli E, Criscuolo M, Delia M, Della Pepa R, Del Principe I, Fanci RR, Farina F, Fracchiolla N, Giordano C, Malagola M, Marchesi F, Piedimonte M, Prezioso L, Quinto AM, Spolzino A, Tisi MC, Trastulli F, Trecarichi EM, Zappasodi P, Tumbarello M, Pagano L; SEIFEM (Sorveglianza Epidemiologica delle Infezioni nelle Emopatie). Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. *Crit Rev Oncol Hematol.* 2021 Feb;158:103203. doi: 10.1016/j.critrevonc.2020.103203. Epub 2020 Dec 31. PMID: 33388453.

32: Nucci M, Jenks J, Thompson GR, Hoenigl M, Dos Santos MC, Forghieri F, Rico JC, Bonuomo V, López-Soria L, Lass-Flörl C, Candoni A, Garcia-Vidal C, Cattaneo C, Buil J, Rabagliati R, Roiz MP, Gudiol C, Fracchiolla N, Campos-Herrero MI, Delia M, Farina F, Fortun J, Nadali G, Sastre E, Colombo AL, Pérez Nadales E, Alastruey-Izquierdo A, Pagano L. Do high MICs predict the outcome in invasive fusariosis? *J Antimicrob Chemother.* 2021 Mar 12;76(4):1063-1069. doi:10.1093/jac/dkaa516. PMID: 33326585.

33: Bassan R, Pavoni C, Intermesoli T, Spinelli O, Tosi M, Audisio E, Marmont F, Cattaneo C, Borlenghi E, Cortelazzo S, Cavattoni I, Fumagalli M, Mattei D, Romani C, Cortelezzi A, Fracchiolla N, Ciceri F, Bernardi M, Scattolin AM, Depaoli L, Masciulli A, Oldani E, Rambaldi A. Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07. *Blood Cancer J.* 2020 Nov 13;10(11):119. doi: 10.1038/s41408-020-00383-2. PMID: 33188164; PMCID: PMC7666128.

34: Borlenghi E, Pagani C, Zappasodi P, Bernardi M, Basilico C, Cairoli R, Fracchiolla N, Todisco E, Turrini M, Cattaneo C, Da Vià M, Ciceri F, Passamonti F, Mancini V, Sciumè M, Cerqui E, Sciumè M, Rossi G. Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL). *J Geriatr Oncol.* 2021 May;12(4):550-556. doi:10.1016/j.jgo.2020.10.004. Epub 2020 Oct 20. PMID: 33097455.

35: Foà R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, Canichella M, Viero P, Ferrara F, Lunghi M, Fabbiano F, Bonifacio M, Fracchiolla N, Di Bartolomeo P, Mancino A, De Propriis MS, Vignetti M, Guarini A, Rambaldi A, Chiaretti S; GIMEMA Investigators. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. *N Engl J Med.* 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272. PMID: 33085860.

36: Guolo F, Fianchi L, Minetto P, Clavio M, Gottardi M, Galimberti S, Rizzuto G, Rondoni M, Bertani G, Dargenio M, Bilio A, Scappini B, Zappasodi P, Scattolin AM, Grimaldi F, Pietrantonio G, Musto P, Cerrano M, D'Arda S, Audisio E, Cignetti A, Pasciolla C, Pavesi F, Candoni A, Gurreri C, Morselli M, Alati C, Fracchiolla N, Rossi G, Caizzi M, Carnevale-Schianca F, Tafuri A, Rossi G, Ferrara F, Pagano L, Lemoli RM. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. *Blood Cancer J.* 2020 Oct 6;10(10):96. doi: 10.1038/s41408-020-00361-8. PMID: 33024084; PMCID: PMC7538937.

37: Passamonti F, Cattaneo C, Arcaini L, et al. ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. *Lancet Haematol.* 2020 Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13. PMID: 32798473; PMCID: PMC7426107.

38: Salmoiraghi S, Cavagna R, Zanghi P, et al. High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG). *Cancers (Basel).* 2020 Aug 11;12(8):2242. doi: 10.3390/cancers12082242. PMID: 32796597; PMCID: PMC7464263.

39: Candoni A, Lazzarotto D, Ferrara F, et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. *Am J Hematol.* 2020 Dec;95(12):1466-1472. doi: 10.1002/ajh.25957. Epub 2020 Aug 31. PMID: 32777149.

40: Fattizzo B, Giannotta JA, Barcellini W, Barbanti MC, Bucelli C, Cassin R, Cattaneo D, Cavallaro F, Ferla V, Fracchiolla NS, Freyrie A, Galassi G, Goldaniga MC, Grifoni FI, Iurlo A, Mangiameli G, Mattiello V, Meli M, Neri A, Noto A, Onida F, Ottani L, Pasquale R, Pettine L, Pompa A, Reda G, Rossi FG, Saporiti GN, Sciumè M, Tagliaferri E, Baldini L. Ensuring continuity of care of hematologic patients during COVID-19

pandemic in a tertiary hospital in Lombardy (Italy). *Blood Adv.* 2020 Jul 14;4(13):2996-2999. doi:10.1182/bloodadvances.2020002120. PMID: 32609844; PMCID: PMC7362383.

41: Posteraro B, De Carolis E, Criscuolo M, Ballanti S, De Angelis G, DelPrincipe MI, Delia M, Fracchiolla N, Marchesi F, Nadali G, Picardi M, Piccioni AL, Verga L, Candoni A, Busca A, Sanguinetti M, Pagano L; SEIFEM group. Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis. *Mycoses.* 2020 Sep;63(9):900-910. doi: 10.1111/myc.13130. Epub 2020 Jul 3. PMID: 32531854

42: Chiaretti S, Messina M, Della Starza I, et al. Philadelphia-like acutelymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMALAL1913. *Haematologica.* 2021 Jun 1;106(6):1559-1568. doi:10.3324/haematol.2020.247973. PMID: 32467145; PMCID: PMC8168510.

43: Fattizzo B, Giannotta JA, Sciumè M, Cattaneo D, Bucelli C, Fracchiolla NS, Onida F, Baldini L, Barcellini W, Iurlo A. Reply to "COVID-19 in persons with haematological cancers": a focus on myeloid neoplasms and risk factors for mortality. *Leukemia.* 2020 Jul;34(7):1957-1960. doi: 10.1038/s41375-020-0877-y. Epub 2020 May 26. PMID: 32457356; PMCID: PMC7250492.

44: Fattizzo B, Rosa J, Giannotta JA, Baldini L, Fracchiolla NS. The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects. *Front Oncol.* 2020 Feb 28;10:273. doi: 10.3389/fonc.2020.00273. PMID:32185137; PMCID: PMC7059203.

45: Cattaneo C, Busca A, Gramegna D, et al. Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study. *Hemasphere.* 2019 Nov 4;3(6):e320. doi: 10.1097/HS9.0000000000000320. PMID: 31976489; PMCID: PMC6924559.

46: Del Principe MI, Buzzatti E, Piciocchi A, et al. Clinical significance of occult central nervous system disease in adult acutelymphoblastic leukemia. A multicenter report from the Campus ALL Network. *Haematologica.* 2021 Jan 1;106(1):39-45. doi: 10.3324/haematol.2019.231704. PMID:31879328; PMCID: PMC7776237.

47: Venditti A, Piciocchi A, Candoni A, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. *Blood.* 2019 Sep 19;134(12):935-945. doi: 10.1182/blood.2018886960. Epub 2019 Aug 8. PMID: 31395600.

48: Bocchia M, Candoni A, Borlenghi E, et al. Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. *Hematol Oncol.* 2019 Oct;37(4):447-455. doi: 10.1002/hon.2663. Epub 2019 Aug 20. PMID: 31385337.

49: Marchesi F, Cattaneo C, Criscuolo M, et al. Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group. A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group. *Am J Hematol.* 2019 Oct;94(10):1104-1112. doi: 10.1002/ajh.25585. Epub 2019 Aug 9. PMID: 31321791.

Milano, 25/01/2023  
Dott. Nicola S Fracchiolla

